Selecta Bioscience News Today

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Volatility and Risk Takeda Pharmaceutical has a beta […]

WuXi Biologics (Cayman) (OTCMKTS:WXXWY – Get Free Report) and Selecta Biosciences (NASDAQ:SELB – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends. Analyst Recommendations This is a summary of […]

Key Insights Selecta Biosciences' significant individual investors ownership suggests that the key decisions are...

Selecta Biosciences, Inc. (NASDAQ:SELB – Get Rating) – Research analysts at SVB Leerink upped their Q1 2023 earnings per share (EPS) estimates for shares of Selecta Biosciences in a report released on Tuesday, March 21st. SVB Leerink analyst J. Schwartz now expects that the company will post earnings of ($0.01) per share for the quarter, […]

Wall Street analysts forecast that Selecta Biosciences, Inc. (NASDAQ:SELB – Get Rating) will report $19.07 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Selecta Biosciences’ earnings. The highest sales estimate is $23.15 million and the lowest is $15.00 million. Selecta Biosciences reported sales of […]

Equities analysts expect that Selecta Biosciences, Inc. (NASDAQ:SELB – Get Rating) will post $18.82 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Selecta Biosciences’ earnings. The lowest sales estimate is $18.00 million and the highest is $19.65 million. Selecta Biosciences reported sales of $11.05 million […]

Equities research analysts expect Selecta Biosciences, Inc. (NASDAQ:SELB – Get Rating) to announce ($0.09) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Selecta Biosciences’ earnings. Selecta Biosciences posted earnings per share of ($0.22) in the same quarter last year, which suggests a positive year-over-year […]

Takeda halted two trials for a narcolepsy candidate to examine a safety signal. The Japanese pharma also signed a gene therapy pact potentially worth over $1 billion with Selecta Biosciences. Moderna has identified "human error" as the source of contaminations in its halted COVID-19 vaccine doses in Japan. And more.

Selecta Biosciences (NASDAQ:SELB) shares are tra...